Zahir Shokouh Taghipour, Mirtalebi Maryammosadate
Shokouh Taghipour zahir, Asssociate professor of clinical and surgical pathology, shahid sadoughi university of medical sciences, Yazd, Iran.
Asian Pac J Cancer Prev. 2012;13(9):4387-91. doi: 10.7314/apjcp.2012.13.9.4387.
Lung carcinoma is the leading cause of cancer mortality worldwide. Although the 5-year survival rate nearly tripled from 5-15% over the last 25 years, the estimated number of deaths still exceeds 1.3 million annually. The overall 5-year survival of lung cancer is only 10% in Europe and 15% in the United States. The aim of the current study was to determine the long-term survival and the effect of certain prognostic factors on survival of patients with lung cancer in Yazd city, Iran.
In this cross-sectional descriptive study, we retrospectively reviewed hospital records and follow-up data of 148 patients with histological proven lung cancer using the cancer data registered between 1998 and 2005 in the pathology department of Shahid Sadoughi educational hospital, Yazd, Iran. Data were extracted from patient documents that included sex, age, clinical manifestations, histopathological report of the tumor and type of treatment given.
Overall survival time in all patients was 8.5 months after diagnosis and there was no significant difference in survival according to sex (p=0.958). Histological analysis revealed that squamous cell carcinoma was the most common histologic type (35%). Kaplan-Meier statistical methods estimated the average survival time for SCC to be better (22.6 months) in comparison with the other types of histology (all of them below 10 months). There was a trend towards significance between type of histology and duration of survival (p=0.08).
It is reasonable to expect that early lung cancer detection, and appropriated treatment, may improve surgical morbidity and mortality. Low survival of lung cancer in our center patients show our shortages in screening programs for early diagnosis. Designing studies with larger sample size that take some other variables like staging of patients is now necessary.
肺癌是全球癌症死亡的主要原因。尽管在过去25年中，肺癌患者的5年生存率几乎增长了两倍，从5%提高到了15%，但每年估计的死亡人数仍超过130万。在欧洲，肺癌患者的总体5年生存率仅为10%，在美国为15%。本研究的目的是确定伊朗亚兹德市肺癌患者的长期生存率以及某些预后因素对其生存的影响。
在这项横断面描述性研究中，我们回顾性分析了1998年至2005年间在伊朗亚兹德市沙希德·萨杜基教育医院病理科登记的148例经组织学证实的肺癌患者的医院记录和随访数据。数据从患者病历中提取，包括性别、年龄、临床表现、肿瘤组织病理学报告和所接受的治疗类型。
所有患者诊断后的总生存时间为8.5个月，按性别分类的生存率无显著差异（p=0.958）。组织学分析显示，鳞状细胞癌是最常见的组织学类型（35%）。与其他组织学类型（均低于10个月）相比，Kaplan-Meier统计方法估计鳞状细胞癌的平均生存时间更好（22.6个月）。组织学类型与生存时间之间存在显著趋势（p=0.08）。
早期肺癌检测和适当治疗有望改善手术发病率和死亡率。我们中心肺癌患者生存率较低，表明我们在早期诊断筛查项目方面存在不足。现在有必要设计样本量更大的研究，并考虑患者分期等其他变量。
